Abstract：
The rapid adoption of next-generation sequencing in clinical oncology has enabled the detection of molecular biomarkers shared between multiple tumor types. These pan-cancer biomarkers include sequence-altering mutations, copy number changes, gene rearrangements, and mutational signatures and have been demonstrated to predict response to targeted therapy. This article reviews issues surrounding current and emerging pan-cancer molecular biomarkers in clinical oncology: technological advances that enable the broad detection of cancer mutations across hundreds of genes, the spectrum of driver and passenger mutations derived from human cancer genomes, and implications for patient care now and in the near future.
摘要：
下一代测序在临床肿瘤学中的快速采用使得能够检测多种肿瘤类型之间共享的分子生物标志物。这些泛癌症生物标志物包括改变序列的突变，拷贝数更改,基因重排,和突变特征，并已被证明可以预测对靶向治疗的反应。本文回顾了围绕临床肿瘤学中当前和新兴的泛癌症分子生物标志物的问题：能够广泛检测数百个基因的癌症突变的技术进步，来自人类癌症基因组的驾驶员和乘客突变谱，以及现在和不久的将来对病人护理的影响。
